MA47111A - Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer - Google Patents

Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer

Info

Publication number
MA47111A
MA47111A MA047111A MA47111A MA47111A MA 47111 A MA47111 A MA 47111A MA 047111 A MA047111 A MA 047111A MA 47111 A MA47111 A MA 47111A MA 47111 A MA47111 A MA 47111A
Authority
MA
Morocco
Prior art keywords
sirpgamma
cancer
treatment
targeting agents
targeting
Prior art date
Application number
MA047111A
Other languages
English (en)
Inventor
xiu-wu Bian
Mark Furth
Molina Sarah Haigh
Hui-Kuan Lin
Chuan Xu
Original Assignee
Univ Wake Forest Health Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wake Forest Health Sciences filed Critical Univ Wake Forest Health Sciences
Publication of MA47111A publication Critical patent/MA47111A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA047111A 2016-12-22 2017-12-19 Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer MA47111A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662438227P 2016-12-22 2016-12-22

Publications (1)

Publication Number Publication Date
MA47111A true MA47111A (fr) 2019-10-30

Family

ID=61022415

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047111A MA47111A (fr) 2016-12-22 2017-12-19 Agents ciblant sirpgamma destinés à être utilisés dans le traitement du cancer

Country Status (4)

Country Link
US (1) US12668628B2 (fr)
EP (1) EP3559037A1 (fr)
MA (1) MA47111A (fr)
WO (1) WO2018118887A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110300764A (zh) 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途
US20230242640A1 (en) * 2018-08-22 2023-08-03 Ose Immunotherapeutics ANTI-SIRPg Compounds
JP2021534769A (ja) * 2018-08-31 2021-12-16 エーエルエックス オンコロジー インコーポレイテッド デコイポリペプチド
MX2021015937A (es) * 2019-06-24 2022-02-03 Amgen Inc Inhibicion de sirp-gamma para el tratamiento del cancer.
JP2023525298A (ja) 2020-05-08 2023-06-15 エレクトラ・セラピューティクス・インコーポレイテッド Sirpアルファおよびsirpベータ1抗体、ならびにそれらの使用
EP4429768A2 (fr) * 2021-11-10 2024-09-18 Electra Therapeutics, Inc. Anticorps sirp gamma et leurs utilisations
CN114085869A (zh) * 2021-11-19 2022-02-25 许川 一种特异性表达人源性sirpg的转基因小鼠的构建方法及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510997A (en) 1893-12-19 Water-closet
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4311688A (en) 1979-10-29 1982-01-19 Serono Laboratories Inc. Composition and method for cancer detection in humans
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5109397A (en) 1988-04-22 1992-04-28 Analogic Corporation X-ray tomography apparatus with lateral movement compensation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5103098A (en) 1989-11-09 1992-04-07 Board Of Regents, The University Of Texas System High resolution gamma ray detectors for positron emission tomography (pet) and single photon emission computed tomography (spect)
US5210421A (en) 1991-06-10 1993-05-11 Picker International, Inc. Simultaneous transmission and emission converging tomography
US5208581A (en) 1991-11-22 1993-05-04 General Electric Company High speed communication apparatus for computerized axial tomography (cat) scanners with matching receiver
CA2163032C (fr) 1993-06-03 2001-02-06 John Landon Fragments d'anticorps a des fins therapeutiques
US5446799A (en) 1993-11-01 1995-08-29 Picker International, Inc. CT Scanner with improved processing efficiency 180 degrees+ fan angle reconstruction system
US5406479A (en) 1993-12-20 1995-04-11 Imatron, Inc. Method for rebinning and for correcting cone beam error in a fan beam computed tomographic scanner system
US5600145A (en) 1995-01-19 1997-02-04 Picker International, Inc. Emission/transmission device for use with a dual head nuclear medicine gamma camera with the transmission source located behind the emission collimator
US5608221A (en) 1995-06-09 1997-03-04 Adac Laboratories Multi-head nuclear medicine camera for dual SPECT and PET imaging with monuniform attenuation correction
EP0914452A2 (fr) 1996-06-17 1999-05-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nouvelles proteines ptp20, pcp-2, bdp1, clk et sirp, produits et procedes connexes
SE9602594D0 (sv) 1996-07-01 1996-07-01 Stefan Nilsson Förfarande och anordning vid datortomografi
US5841140A (en) 1997-01-08 1998-11-24 Smv America, Inc. Gamma camera for pet and spect studies
US5946371A (en) 1997-12-08 1999-08-31 Analogic Corporation Method and apparatus for volumetric computed tomography scanning with offset symmetric or asymmetric detector system
CA2226962A1 (fr) 1998-02-16 1999-08-16 Marie Sarfati Utilisation d'agents liants a cd47 et ces ligands pour le traitement ou prophylaxie de maladies inflammatoire, autoimmunitaire et allergique et pour le traitement de rejet de greffons
US6115446A (en) 1999-04-09 2000-09-05 Arch Development Corp. Fast reconstruction of fan-beam CT and SPECT
EP1048299A1 (fr) 1999-04-28 2000-11-02 Faculteit der Geneeskunde van de Vrije Universiteit Procédé pour l'inhibition du fonctionemment cellulaire dans la therapie antiinflammatoire et anticancéreuse
EP1244707A1 (fr) 1999-11-30 2002-10-02 Eberhard-Karls-Universität Tübingen Universitätsklinikum Anticorps diriges contre les proteines regulatrices de signal
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
WO2006110728A2 (fr) 2005-04-12 2006-10-19 The Uab Research Foundation Agregats de tegument immunogenes
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
WO2009036379A2 (fr) 2007-09-14 2009-03-19 Adimab, Inc. Bibliothèques d'anticorps synthétiques rationnelles et leurs utilisations
US7973019B1 (en) 2007-10-03 2011-07-05 Alcon Research, Ltd. Transferrin/transferrin receptor-mediated siRNA delivery
JP2011500005A (ja) 2007-10-11 2011-01-06 ユニバーシティー ヘルス ネットワーク ヒト造血幹細胞の生着を増加させるためのSIRPα−CD47相互作用の調節およびそのための化合物
CA2711370C (fr) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Marqueurs des cellules souches de la leucemie myeloide aigue
PT3056515T (pt) 2008-01-15 2019-07-19 Univ Leland Stanford Junior Métodos para manipulação da fagocitose mediada por cd47
EP2111869A1 (fr) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions et procédés pour renforcer le système immunitaire
US20100162416A1 (en) * 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
CN101880324B (zh) 2010-05-25 2012-10-17 中国人民解放军第二军医大学 一种抗人SIRPα的单克隆抗体及其细胞株、制备方法和应用
MX381912B (es) 2010-07-16 2025-03-13 Adimab Llc Colecciones de anticuerpos.
EP2593595B1 (fr) 2010-07-16 2020-03-11 Avantgen, Inc. Nouveaux peptides et leurs utilisations
WO2013056352A1 (fr) 2011-10-19 2013-04-25 University Health Network Anticorps et fragments d'anticorps ciblant sirp-alpha et leur utilisation pour le traitement de cancers hématologiques
EP2934577A1 (fr) 2012-12-19 2015-10-28 Adimab, LLC Analogues d'anticorps multivalents, et leurs procédés de préparation et d'utilisation
CN103665165B (zh) 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
US20160312295A1 (en) 2013-12-17 2016-10-27 Merck Sharp & Dohme Corp. Gene signature biomarkers of tumor response to pd-1 antagonists
US11046763B2 (en) 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
WO2015138600A2 (fr) 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anticorps anti-sirp-alpha et anticorps bispécifiques de stimulation des macrophages
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
WO2016049276A1 (fr) 2014-09-25 2016-03-31 Moffitt Genetics Corporation Biomarqueurs de tumeurs pronostiques
AU2015329696A1 (en) * 2014-10-10 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting CD47
EP3012271A1 (fr) 2014-10-24 2016-04-27 Effimune Procédé et compositions pour induire la différenciation de cellule suppressives dérivées de myéloïde pour traiter le cancer et les maladies infectieuses
WO2016065329A1 (fr) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions et procédés pour induire la phagocytose de cellules positives de classe i du cmh et pour contrer la résistance aux agents anti-cd47/sirpa
DK3298043T3 (da) * 2015-05-18 2021-02-15 Ab Initio Biotherapeutics Inc SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse
US10946042B2 (en) * 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
CN110300764A (zh) 2017-02-17 2019-10-01 Ose免疫疗法 抗SIRPg抗体的新用途

Also Published As

Publication number Publication date
EP3559037A1 (fr) 2019-10-30
US12668628B2 (en) 2026-06-30
WO2018118887A1 (fr) 2018-06-28
US20230139592A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
PL3416631T3 (pl) Środki terapeutyczne do leczenia chorób neurodegeneracyjnych
PL3600309T3 (pl) Skojarzenia terapeutyczne do leczenia chorób wątroby
PL4272834T3 (pl) Zastosowanie terapeutyczne mitochondriów i połączonych środków mitochondrialnych
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
MA45192A (fr) Traitement d'association
EP3431102A4 (fr) Médicament thérapeutique induisant des lésions cellulaires à utiliser dans le traitement du cancer
PL3429571T3 (pl) Kombinacje inhibitorów lsd1 do zastosowania w leczeniu chorób nowotworowych
EP3436002A4 (fr) Combinaisons pharmaceutiques pour le traitement du cancer
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
EP3432888A4 (fr) Traitement du cancer avec tg02
EP3474854A4 (fr) Associations médicamenteuses pour le traitement du cancer
EP3383404A4 (fr) Traitement du cancer à l'aide de 2-désoxy-2-fluoro-l-fucose en association avec un inhibiteur de point de contrôle
EP3503904A4 (fr) Traitement par ascaroside de l'oesophagite à éosinophiles
EP3302501A4 (fr) Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
PL3490560T3 (pl) Niraparyb do stosowania w sposobie leczenia nowotworu prostaty
MA46608A (fr) Formulation liposomale destinée à être utilisée dans le traitement du cancer
EP3556368A4 (fr) Agent thérapeutique contre l'onychomycose
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3490548A4 (fr) Administration de promédicaments activés par l'hypoxie en combinaison à des agents immunomodulateurs pour le traitement du cancer
CY1127309T1 (el) Ebselen για χρηση στη θεραπεια της νοσου meniep
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
EP3347010A4 (fr) Synthèse et composition d'agents thérapeutiques photodynamiques pour le traitement ciblé du cancer
HUE053927T2 (hu) Farneziltranszferáz inhibitorok rák kezelésében történõ alkalmazásra
EP3503887A4 (fr) Combinaisons pour le traitement du cancer